Table 5.

Relationship of HIV status to metabolic and cardiovascular parameters among obese subjects (35 HIV-infected, 30 HIV-uninfected)

Outcome variable	Regression coefficient for HIV status*	p-value
Glucose metabolism assessments
HOMA2 beta-cell function	−0.04	0.79
HOMA2 insulin sensitivity	0.13	0.31
OGIS 120	−0.06	0.69
Hemoglobin A1c	−0.16	0.21
Insulin	−0.12	0.34
Adipokine levels
Leptin	−0.08	0.35
Adiponectin	−0.01	0.96
Resistin	−0.40	0.004
Plasma lipids
Total cholesterol	0.11	0.03
HDL	−0.13	0.04
LDL	0.08	<0.01
Triglycerides	0.20	0.03
Inflammation biomarkers
High sensitivity C-reactive protein, mg/l	−0.01	0.92
Interleukin-6, pg/ml	0.04	0.70
Tumor necrosis factor-alpha receptor 1, ng/ml	0.03	0.81
Soluble CD163	0.13	0.33
Soluble CD14	0.54	<0.01
Vascular adhesion biomarkers
Intercellular adhesion molecule 1 (ICAM-1), ng/ml	0.33	0.01
Vascular cell adhesion molecule 1 (VCAM-1), ng/ml	0.31	0.02
Vascular ultrasound measurements
Carotid bulb intima-media thickness (IMT)	−0.09	0.42
Common carotid IMT	−0.04	0.74
Internal carotid IMT	−0.18	0.19
Brachial artery flow-mediated dilation	0.05	0.76

Multivariable model adjusted for age, sex, race, HIV status, smoking status, DEXA total fat mass, and interaction term for DEXA fat mass and HIV status

^*In models where the interaction term p-value was >0.1, the regression coefficient for HIV status is calculated after removing the interaction term from the model

Abbreviations: DEXA, dual-energy x-ray absorptiometry; HLD, high-density lipoprotein; HOMA, Homeostasis Model Assessment; OGIS, oral glucose insulin sensitivity; LDL, low-density lipoprotein